Milestone Pharmaceuticals (MIST) Return on Capital Employed (2019 - 2022)
Milestone Pharmaceuticals' (MIST) quarterly Return on Capital Employed came in at 76.85% in Q3 2022, down 5075.0% YoY from 1.54% in Q3 2021, and down 53.25% on a QoQ basis from 50.15% in Q2 2022.
Milestone Pharmaceuticals (MIST) Return on Capital Employed (2019 - 2022) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 4 years of Return on Capital Employed data on file, last reported at 76.85% in Q3 2022.
- Quarterly Return on Capital Employed fell 5075.0% year-over-year to 76.85% in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 76.85% (down 5075.0% YoY) and the FY2021 annual result came in at 33.61%, up 523.0% from the prior year.
- Return on Capital Employed eased to 76.85% in Q3 2022, from 50.15% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 23.95% in Q2 2021 to a low of 76.85% in Q3 2022.
- A 4-year average of 45.39% and a median of 39.96% in 2019 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed surged 4241 bps — and 2022, when it slumped 5075 bps.
- Tracing MIST's Return on Capital Employed over 4 years: stood at 46.55% in 2019, then grew by 12 bps to 41.15% in 2020, then climbed by 13 bps to 35.88% in 2021, then sank by 114 bps to 76.85% in 2022.
- The last three Return on Capital Employed figures came in at 76.85% (Q3 2022), 50.15% (Q2 2022), and 35.88% (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | - |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 7.88% |
| 10 | Milestone Pharmaceuticals | 43.11 Mn | -128.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -76.85% |
| Jun 30, 2022 | -50.15% |
| Dec 31, 2021 | -35.88% |
| Sep 30, 2021 | -26.10% |
| Jun 30, 2021 | -23.95% |
| Mar 31, 2021 | -33.63% |
| Dec 31, 2020 | -41.15% |
| Sep 30, 2020 | -63.98% |
| Jun 30, 2020 | -66.36% |
| Mar 31, 2020 | -58.49% |
| Dec 31, 2019 | -46.55% |
| Sep 30, 2019 | -35.57% |
| Jun 30, 2019 | -38.02% |
| Mar 31, 2019 | -38.76% |